Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX, page-46

Therefore all your talk earlier was basically for what purpose over past month? Stokdog - you told us you placed a value closer to market cap of 100 million upon successful results yet you sold before results came out ?? haha who are you people - results were good and now that you have your one of the first to make a point of saying results were late and only 27% of patients at mid point - !! that's because the rest of the human trials are yet to hit mid point but to date its been highly successful and now you suggesting the results not good because you dont hold??
-- stokdog you posted this below on 9 September #19046232 :

#19046232
MAJOR COMPARISON

I need to ALERT you all to the fact that Retrophin announced their Proeinuria results for a very smilar phase II trial for Kidney Disease using a diffent combination of 2 receptor blockers. Basically they achieved a 44% mean reduction and the share priced rocketed from $16 to $21 and they put on a approx US$100m in value. See the chart

If Dimerix interim results for DMX200 shows a reduction in preinuria as per the animal model of 50% or more using the angiotensin Il Type 1 (AT1R) and the chemokine 2 receptors (CCR2) then its market cap will soar from $20 million and in line with its US peers just on the potential alone and its competitive advantage in this space. That’s why I place a value closer to $100m market cap on positive results.

The rat model data was very impressive. See link.
http://dimerix.com/wp-content/uploads/15.05.13.Sun-Biomedical-to-Acquire-Dimerix-Bioscience1.pdf
GET SET


good luck to all long term holders - i am finished with posting

GLTA g101